Hi it's Diane, on my mind, the new class of weight loss drugs.

Last week the FDA approved a medication said to be the most potent yet in the treatment

of chronic obesity, a condition that affects more than 100 million American adults.

Developed by Eli Lilly, zipbound is the latest in the arsenal of tools doctors now ahead to help

patients lose weight others include Ozempic Wagoi and Munjaro.

Like this total new world, the weight control,

and it's changing things.

It's changing perspectives for people with obesity. Gino-Kolata is a

reporter for people with obesity.

She know Colada is a reporter for the New York Times.

She's been reporting on the issue of obesity for decades.

She joined me Thursday morning to break down how these drugs work,

possible side effects, and what's next in the development of obesity medications.

Gina, tell me about the latest weight loss drug

to be approved by the FDA. Tell me what it is and what it does, how it works.

Well, that's a good question how it works because this drug isepbound and other ones like it or similar to it were

discovered by accident and it's not entirely clear how it works. It's a gut hormone and it tells people that they're not

hungry anymore. So it diminishes people's appetites but no one really knows why.

Apparently these drugs do reach the brain,

various parts all over the brain,

and they're kind of a mystery still.

I mean, people knew that this was the way

...